Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: A single-center series of 37 patients

Blood

Volumn 117, Issue 10, 2011, Pages 2783-2790

  Arnaud, Laurent ^a,b   Gorochov, Guy ^a,b,c   Charlotte, Frédéric ^a,c   Lvovschi, Virginie ^a   Parizot, Christophe ^a   Larsen, Martin ^b,c   Ghillani Dalbin, Pascale ^a   Hervier, Baptiste ^a   Kahn, Jean Emmanuel ^d   Deback, Claire ^a   Musset, Lucile ^a   Amoura, Zahir ^a,b,c   Haroche, Julien ^a,c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d FOCH HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CHEMOKINE; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; MONOCYTE CHEMOTACTIC PROTEIN 1; PEGINTERFERON; PEGINTERFERON ALPHA; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; ERDHEIM CHESTER DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPOTHESIS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; SYMPTOM; SYSTEMIC DISEASE; TH1 CELL; TREATMENT OUTCOME;

EID: 79953111158     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-313510     Document Type: Article

References (38)

1. Chester W. Über lipoidgranulomatose. Virchows Arch Pathol Anat. 1930;279:561-602.
2. Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore). 2004;83(6):371-392. (Pubitemid 39541113)
3. Veyssier-Belot C, Cacoub P, Caparros-Lefebvre D, et al. Erdheim-Chester disease. Clinical and radiologic characteristics of 59 cases. Medicine (Baltimore). 1996;75(3):157-169. (Pubitemid 26159212)
4. de Abreu MR, Castro MO, Chung C, et al. Erdheim-Chester disease: case report with unique postmortem magnetic resonance imaging, high-resolution radiography, and pathologic correlation. Clin Imaging. 2009;33(2):150-153.
5. Myra C, Sloper L, Tighe PJ, et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol. 2004;88(6):844-847. (Pubitemid 38725610)
6. Haroche J, Amoura Z, Trad SG, et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum. 2006;54(10):3330-3336. (Pubitemid 44622105)
7. Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116(20):4070- 4076.
8. Haroche J, Amoura Z, Charlotte F, et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood. 2008;111(11):5413-5415.
9. Mossetti G, Rendina D, Numis FG, Somma P, Postiglione L, Nunziata V. Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin- 6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease. Clin Exp Rheumatol. 2003;21(2):232-236. (Pubitemid 36519571)
10. Boissel N, Wechsler B, Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med. 2001;135(9):844-845. (Pubitemid 33051276)
11. Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum. 2006;54(12):4018-4022. (Pubitemid 44955906)
12. Dagna L, Girlanda S, Langheim S, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford). 2010;49(6):1203-1206.
13. Arnaud L, Malek Z, Archambaud F, et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum. 2009;60(10):3128-3138.
14. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260(5107):547-549. (Pubitemid 23161621)
15. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol. 1990;145(11):3796-3806.
16. Gabay C, Marinova-Mutafchieva L, Williams RO, et al. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. Arthritis Rheum. 2001;44(2):451-462.
17. Chetoui N, Boisvert M, Gendron S, Aoudjit F. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology. 2010;130(3):418-426.
18. Saini M, Pearson C, Seddon B. Regulation of T cell-dendritic cell interactions by IL-7 governs T-cell activation and homeostasis. Blood. 2009;113(23):5793-5800.
19. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504-1508.
20. Weitzmann MN, Cenci S, Rifas L, Brown C, Pacifici R. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood. 2000;96(5):1873-1878. (Pubitemid 30661073)
21. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol. 2003;24(1):25-29. (Pubitemid 35462110)
22. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23:307-336. (Pubitemid 40563172)
23. Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med. 1993;178(5):1655-1663.
24. Mitani Y, Takaoka A, Kim SH, et al. Cross talk of the interferon-alpha/beta signalling complex with gp130 for effective interleukin-6 signalling. Genes Cells. 2001;6(7):631-640. (Pubitemid 32747202)
25. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5(8):919-923. (Pubitemid 29372419)
26. Amadori M. The role of IFN-alpha as homeostatic agent in the inflammatory response: a balance between danger and response? J Interferon Cytokine Res. 2007;27(3):181-189. (Pubitemid 46435485)
27. Yarilina A, Ivashkiv LB. Type I interferon: a new player in TNF signaling. Curr Dir Autoimmun. 2010;11:94-104.
28. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007;13(8):2422-2428. (Pubitemid 46698593)
29. MacQuillan GC, Mamotte C, Reed WD, Jeffrey GP, Allan JE. Upregulation of endogenous intrahepatic interferon stimulated genes during chronic hepatitis C virus infection. J Med Virol. 2003;70(2):219-227. (Pubitemid 36520630)
30. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-1492. (Pubitemid 28543496)
31. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14(1):7-17. (Pubitemid 26019991)
32. Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106(9):2992-2994. (Pubitemid 41565890)
33. Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(2):383-391.
34. Gourh P, Arnett FC, Assassi S, et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations [abstract]. Arthritis Res Ther. 2009;11(5):R147.
35. Szodoray P, Alex P, Knowlton N, et al. Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand. Rheumatology (Oxford). 2010;49(10):1867-1877.
36. Stabler T, Piette JC, Chevalier X, Marini-Portugal A, Kraus VB. Serum cytokine profiles in relapsing polychondritis suggest monocyte/macrophage activation. Arthritis Rheum. 2004;50(11):3663-3667. (Pubitemid 39488695)
37. Bozza FA, Salluh JI, Japiassu AM, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis [abstract]. Crit Care. 2007;11(2):R49.
38. Hillenbrand A, Knippschild U, Weiss M, et al. Sepsis induced changes of adipokines and cytokines: septic patients compared to morbidly obese patients. BMC Surg. 2010;10:26.